Celltrion Gears Up For Phase III Trial For Biosimilar Of Roche’s Rituxan
This article was originally published in PharmAsia News
Executive Summary
Korea’s Celltrion said it is on path to a new Phase III trial design of a biosimilar of Roche’s Rituxan after presenting positive Phase I trial data in San Diego in late October.